DHR
Danaher Corporation
$178.19
▲ 0.6%Updated Today 7:15 PM ET
▼ Down 8.9% over the last 12 months
Market Cap
$125.40B
P/E
34.05x
Forward P/E (est.)
33.93x
ROE
7.1%
Revenue Growth
4.0%
EPS Growth
0.3%
Profit Margin
14.9%
FCF Yield
6.0%
Debt / Equity
0.35x
ROIC
5.0%
Interest Coverage
16.4x
Current Ratio
1.87x
Dividend Yield
0.9%
Implied Growth (rev. DCF)
4.6%
Rating Score
48/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what DHR's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. DHR trades near $178.19, below its 50-day average ($179.92) and 200-day average ($204.36). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 46 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. DHR's is $4.86 (~2.7% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month DHR found buyers near $164.10 (support) and sellers near $189.21 (resistance); its 52-week range is $160.93–$242.80. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.7× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Danaher Corporation (DHR) is a large-cap company in the Life Sciences Tools & Services industry, part of the Health Care sector of the S&P 500, with a market value around $125.40B.
In its latest reported year it generated about $24.57B in revenue and $3.61B in net profit.
Our model rates DHR Neutral (48/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
-0.2%
Revenue moved from $24.80B in 2021 to $24.57B in 2025, a -0.2% compound annual growth rate. The most recent year was roughly flat (4.0%) year over year. Slower, mature growth is common for established businesses.
Gross Margin
59.1%
Operating Margin
19.1%
Net Margin
14.7%
ROE
7.1%
Danaher Corporation keeps about 14.9% of each sales dollar as net profit, with a 59.1% gross margin and 19.1% operating margin. Return on equity is 7.1% and return on invested capital about 5.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$18.48B
Net Debt
$12.80B
Net Debt / EBITDA
2.73x
Debt / Equity
0.35x
Leverage: debt-to-equity is 0.4x, and operating profit covers interest about 16.4x, with a current ratio of 1.9x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $18.48B of total debt against $5.69B of cash.
Operating CF
$6.42B
Free Cash Flow
$5.26B
FCF Margin
21.4%
In the latest year Danaher Corporation produced about $6.42B of operating cash flow and $5.26B of free cash flow after capital spending. That is a free-cash-flow yield of about 6.0% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
34.05x
P/S
5.23x
P/B
3.01x
EV / EBITDA
20.59x
DHR trades at 34.0x trailing earnings (about 33.9x on estimated forward earnings), 5.2x sales, and 3.0x book value. Reverse-engineering today's price implies the market expects roughly 4.6% long-term free-cash-flow growth. That is a premium multiple that needs growth to justify it.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How DHR stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), DHR ranks #38 of 59 by our overall rating. It trades at a premium versus the sector on earnings (34x P/E vs. 25.4x median) with a lower return on equity (7.1% vs. 14.9%) and slower revenue growth (4.0% vs. 7.9%).
P/E vs sector
34x
median 25.4x
ROE vs sector
7.1%
median 14.9%
Growth vs sector
4.0%
median 7.9%
Sector rank
#38
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$126.70 – $215.38
vs. $178.19 today · expected CAGR -7% – 4%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $25.55B | $26.57B | $27.64B | $28.74B | $29.89B |
| Net income | $3.83B | $3.99B | $4.15B | $4.31B | $4.48B |
| EPS | $5.42 | $5.63 | $5.86 | $6.09 | $6.33 |
| Share price (low) | $108.30 | $112.63 | $117.14 | $121.82 | $126.70 |
| Share price (high) | $184.11 | $191.48 | $199.13 | $207.10 | $215.38 |
| CAGR (low–high) | -39% / 3% | -20% / 4% | -13% / 4% | -9% / 4% | -7% / 4% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for DHR:
- Healthy free-cash-flow yield (~6.0%) funds buybacks and dividends.
- A conservative balance sheet (debt/equity 0.4x) lowers risk.
The case against DHR:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Valuation risk — at 34.0x earnings, disappointing results could compress the multiple.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Danaher Corporation is a large-cap health care business growing at a mature pace, with solid profitability, and a sound balance sheet. It trades at 34.0x earnings, which our model scores Neutral (48/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.